Verastem Stock In The News

VSTM Stock  USD 4.57  0.52  12.84%   
Our overall analysis of Verastem's news coverage and content from conventional and social sources shows investors' bearish mood towards Verastem. The specific impact of Verastem news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Verastem's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Verastem headlines in addition to utilizing other, more conventional financial analysis modules. Check out Verastem Backtesting and Verastem Hype Analysis.
To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.

Verastem Today Top News and Investor Outlook

Yahoo News
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
https://finance.yahoo.com/news/3-off-beaten-path-stocks-140804854.html
 Bullish
Yahoo News
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
https://finance.yahoo.com/news/small-stakes-big-rewards-3-211714080.html
 Bullish
Yahoo News
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
https://finance.yahoo.com/news/verastem-oncology-announces-promotion-dan-110000060.html
 Neutral
Yahoo News
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/verastem-oncology-announces-inducement-grants-200500019.html
 Neutral
Yahoo News
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
https://finance.yahoo.com/news/verastem-oncology-announces-design-confirmatory-200500596.html
 Neutral
Yahoo News
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
https://finance.yahoo.com/news/verastem-oncology-announces-pricing-85-090000446.html
 Neutral
Yahoo News
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200000963.html
 Neutral
Yahoo News
Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged
https://finance.yahoo.com/m/5985da9b-fb93-362c-9e7e-4555f741555d/verastem-stock-is.html
 Neutral
Yahoo News
Verastem Oncology Announces Reverse Stock Split
https://finance.yahoo.com/news/verastem-oncology-announces-reverse-stock-131100164.html
 Bullish
Yahoo News
Updated Data from Part A of Verastem Onc...
https://finance.yahoo.com/news/updated-data-part-verastem-oncologys-210500253.html
 Neutral

Verastem Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Verastem and other traded companies coverage with news coverage. We help investors stay connected with Verastem headlines for the 29th of November to make an informed investment decision based on correlating the impacts of news items on Verastem Stock performance. Please note that trading solely based on the Verastem hype is not for everyone as timely availability and quick action are needed to avoid losses.
Verastem's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Verastem investors visualize upcoming and past events in order to time the market based on Verastem noise-free hype analysis.
Verastem stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Verastem earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Verastem that are available to investors today. That information is available publicly through Verastem media outlets and privately through word of mouth or via Verastem internal channels. However, regardless of the origin, that massive amount of Verastem data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Verastem news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Verastem relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Verastem's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Verastem alpha.

Verastem Largest EPS Surprises

Earnings surprises can significantly impact Verastem's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-09
2022-03-31-0.08-0.09-0.0112 
2023-03-14
2022-12-31-0.1-0.080.0220 
2021-08-02
2021-06-30-0.08-0.1-0.0225 
2022-11-03
2022-09-30-0.12-0.090.0325 
2016-11-07
2016-09-30-0.24-0.210.0312 
2021-03-18
2020-12-31-0.08-0.12-0.0450 
View All Earnings Estimates

Verastem Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Verastem Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
Macroaxis News
18th of November 2024
Disposition of 3245 shares by Paterson Dan of Verastem at 2.16 subject to Rule 16b-3
at MacroaxisInsider 
Gurufocus Stories at Macroaxis
15th of November 2024
OrbiMed Advisors LLCs Strategic Acquisition of Verastem Inc Shares
at gurufocus.com 
seekingalpha News
7th of November 2024
Verastem GAAP EPS of -0.60 beats by 0.14
at seekingalpha.com 
Macroaxis News
5th of November 2024
Disposition of 812 shares by Paterson Dan of Verastem at 3.84 subject to Rule 16b-3
at MacroaxisInsider 
news
18th of October 2024
Verastems Buy Rating Reiterated at HC Wainwright
at thelincolnianonline.com 
businesswire News
17th of October 2024
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib ...
at businesswire.com 
businesswire News
9th of October 2024
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data ...
at businesswire.com 
Yahoo News
7th of October 2024
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635
at finance.yahoo.com 
news
2nd of October 2024
Guggenheim Initiates Coverage on Verastem
at thelincolnianonline.com 
Investing News at Macroaxis
18th of September 2024
Verastem director Brian Stuglik sells shares worth 1,680
at investing.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Verastem in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Verastem's short interest history, or implied volatility extrapolated from Verastem options trading.
When determining whether Verastem is a strong investment it is important to analyze Verastem's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Verastem's future performance. For an informed investment choice regarding Verastem Stock, refer to the following important reports:
Check out Verastem Backtesting and Verastem Hype Analysis.
To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.14)
Revenue Per Share
0.331
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.47)
Return On Equity
(1.37)
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.